Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial.

Publisher: American Medical Association Country of Publication: United States NLM ID: 101676033 Publication Model: Print Cited Medium: Internet ISSN: 2380-6591 (Electronic) NLM ISO Abbreviation: JAMA Cardiol Subsets: MEDLINE

Original Publication: [Chicago, Illinois] : American Medical Association, [2016]-

Coronary Artery Disease*/etiology ; Coronary Artery Disease*/surgery ; Mammary Arteries*/transplantation; Aged ; Coronary Artery Bypass/methods ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome ; Vascular Patency

Importance: The relative safety and patency of skeletonized vs pedicled internal mammary artery grafts in patients undergoing coronary artery bypass graft (CABG) surgery are unknown.
Objective: To investigate the association of skeletonized vs pedicled harvesting with internal mammary artery graft patency and clinical outcomes 1 year after CABG surgery.
Design, Setting, and Participants: This study was a post hoc analysis of the multicenter, randomized, double-blind, placebo-controlled Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) clinical trial, which enrolled 27 395 patients from 602 centers in 33 countries from March 2013 through May 2016. Eligibility criteria for the trial included CABG surgery for coronary artery disease with at least 2 grafts implanted and an estimated glomerular filtration rate of at least 30 mL/min. A total of 1002 of 1448 patients were randomized to the CABG arm of the COMPASS trial and underwent skeletonized (282 [28.1%]) or pedicled (720 [71.9%]) internal mammary artery harvesting. The patients had evaluable angiography results 1 year after surgery. Data were analyzed from October 11, 2019, to May 14, 2020.
Interventions: Patients underwent graft harvesting with either the pedicled technique or skeletonized technique.
Main Outcomes and Measures: The primary outcome was graft occlusion 1 year after CABG surgery, as assessed by computed tomography angiography.
Results: A total of 1002 patients underwent skeletonized (282 [28.1%]; mean [SD] age, 65.9 [8.1] years; 229 men [81.2%]; 194 White patients [68.8%]) or pedicled (720 [71.9%]; mean [SD] age, 64.8 [7.6] years; 603 men [83.8%]; 455 White patients [63.2%]) internal mammary artery harvesting. Rates of internal mammary artery graft occlusion 1 year after CABG surgery were higher in the skeletonized group than in the pedicled group (33 of 344 [9.6%] vs 30 of 764 [3.9%]; graft-level adjusted odds ratio, 2.41; 95% CI, 1.39-4.20; P = .002), including the left internal mammary artery to left anterior descending artery (21 of 289 [7.3%] vs 25 of 725 [3.4%]; graft-level adjusted odds ratio, 2.10; 95% CI, 1.14-3.88, P = .02). After a mean follow-up of 23 months, skeletonized graft harvesting was also associated with a higher rate of major adverse cardiovascular events (20 [7.1%] vs 15 [2.1%]; adjusted hazard ratio, 3.19; 95% CI, 1.53-6.67; P = .002) and repeated revascularization (14 [5.0%] vs 10 [1.4%]; adjusted hazard ratio, 2.75; 95% CI, 1.10-6.88; P = .03).
Conclusions and Relevance: This post hoc analysis of the COMPASS randomized clinical trial found that harvesting of the internal mammary artery during CABG surgery using a skeletonized technique was associated with a higher rate of graft occlusion and worse clinical outcomes than the traditional pedicled technique. Future randomized clinical trials are needed to establish the safety and patency of the skeletonized technique.
Trial Registration: ClinicalTrials.gov Identifier: NCT01776424.

Erratum in: JAMA Cardiol. 2021 Aug 18;:null. (PMID: 34406323)
Comment in: JAMA Cardiol. 2022 Sep 1;7(9):987-988. (PMID: 35830168)
Comment in: JAMA Cardiol. 2022 Sep 1;7(9):988-989. (PMID: 35830191)

Investigator: R Diaz; AM Tonkin; JD Varigos; PB Verhamme; A Avezum; LS Piegas; GR Dagenais; EM Lonn; F Lanas; J Zhu; L Liu; Y Liang; P Lopez-Jaramillo; P Widimsky; C Torp-Pedersen; C Felix; KP Metsarinne; PG Steg; V Aboyans; G Ertl; S Stoerk; K Keltai; M Keltai; M O'Donnell; KA Fox; A Kakkar; BS Lewis; AP Maggioni; M Hori; K Yusoff; M Alings; AL Dans; TJ Guzik; D Vinereanu; NG Pogosova; PJ Commerford; JH Kim; L Ryden; AN Parkhomenko; DL Bhatt; KRH Branch; JL Probstfield; S Anand; J Bosch; S Connolly; JW Eikelboom; R Hart; A Lamy; P Moayeddi; M Sharma; S Yusuf; S Berkowitz; E Muehlhofer

ClinicalTrials.gov NCT01776424

Date Created: 20210616 Date Completed: 20220428 Latest Revision: 20221002

20221213

PMC8209583

10.1001/jamacardio.2021.1686

34132753